- Statin therapy is associated with a reduced risk of revision hip and knee surgery.
- Timing of first exposure to statin therapy appear to influence the risk of revision surgery with first exposure within 5 years of surgery being associated with a reduction in risk.
Why this matters
- Findings suggest that statins may potentially provide an approach to reducing the risk of revision surgery in patients undergoing primary THA/TKA.
- Study used data from the Clinical Practice Research Datalink (CPRD) and identified 151,305 participants who underwent a primary THA (n=78,594) or TKA (n=72,711) from 1988 -2016.
- Primary outcome: all-cause revision arthroplasty.
- Funding: John Charnley Trust and others.
- Of 151,305 participants, 65,032 (43%) were exposed to statins during follow-up and 3500 (2.3%) had revision arthroplasty.
- In a propensity score adjusted model, statins exposure was associated with a lower risk for revision arthroplasty vs non-exposure (aHR, 0.82; 95% CI, 0.75-0.90).
- Participants first exposed to statins in 0-1 year (aHR, 0.82; 95% CI, 0.74-0.91), 1-5 years (aHR, 0.76; 95% CI, 0.65-0.90) and >5 years (aHR, 0.95; 95% CI, 0.76-1.19) following THA/TKA had a reduced risk for revision arthroplasty vs those not exposed.
- Compared to participants exposed to statins for 5 years had lower risk for revision arthroplasty (aHR, 0.74; 95% CI, 0.62-0.88).
- Observational design.